Here’s what you should know.
1. The Rezūm system is a minimally invasive therapy system that treats benign prostatic hyperplasia.
2. Boston Scientific paid $306 million cash and up to $100 million more in potential commercial milestone payments over the next four years. But Boston Scientific has an existing minority investment in NxThera. The existing investment means the company will only pay $240 million at closing and up to $85 million in milestone payments.
3. Boston Scientific Senior Vice President and Urology and Pelvic Health President Dave Pierce said, “The Rezūm system is an innovative therapy for men with symptomatic BPH that helps patients with a minimally invasive approach while reducing the cost and unwanted side effects that come with taking maintenance medications.”
More articles on supply chain:
7 things for ASC leaders to know for Thursday — March 22, 2018
10 things to know about Regent Surgical Health
How freight management uncovers hidden cost savings in ASC supply chain
